IRD
Opus Genetics, Inc.
Biotechnology · Healthcare · United States
3.67
close · 2026-10-30
value
66
cheaper than peers66
quality
1
stronger fundamentals1
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | 23.7% | 99 |
| cash flow yield, 3 years ago | 4.7% | 93 |
| cash flow yield, 2 years ago | -0.4% | 82 |
| earnings yield, 2 years ago | -12.5% | 56 |
| cash flow yield, 1 year ago | -8.4% | 54 |
| cash flow yield, latest year | -11.5% | 47 |
| earnings yield, latest year | -21.8% | 39 |
| price to sales | 30.98× | 29 |
| earnings yield, 1 year ago | -58.6% | 21 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | -73.8% | 11 |
| operating margin | -2182.8% | 11 |
| return on equity | -4796.5% | 0 |
3 of 4 measures available
Facts
| market cap | $305M |
| free cash flow | -$38.6M |
| employees | 27 |
| first trade | 2005-11-10 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-19 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -0.80 | -2.15 | -0.46 | 0.87 | not reported |
| free cash flow | -$35.3M | -$25.6M | -$1.1M | $14.3M | not reported |
| net income | -$49.6M | -$57.5M | -$10.0M | $17.9M | not reported |
| revenue | $14.2M | $11.0M | $19.0M | $39.9M | not reported |
| unusual items | -$11.5M | -$27.9M | $80,000 | not reported | -$33.8M |